

new FDA rule with far-reaching implications for the nation's clinical laboratory sector and the many thousands of health care practitioners the new rule would regulate. Defendants have stated that they intend to begin enforcing requirements under the new rule beginning May 6, 2025.

Plaintiffs' counsel conferred with FDA's counsel before filing this submission. FDA takes no position on this request for oral argument.

Dated: January 17, 2025

/s/ Michael D. Shumsky
Michael D. Shumsky (*admitted pro hac vice*)
D.C. Bar. No. 495078
Jeffrey N. Gibbs (*admitted pro hac vice*)
D.C. Bar. No. 385294
Allyson B. Mullen (*admitted pro hac vice*)
D.C. Bar No. 1018481
Sara W. Koblitz (*admitted pro hac vice*)
D.C. Bar No. 1017284
Steven J. Gonzalez (*admitted pro hac vice*)
D.C. Bar No. 1600850
Sarah L. Wicks (*admitted pro hac vice*)
D.C. Bar No. 1719206
HYMAN, PHELPS & McNAMARA, P.C.
700 Thirteenth Street NW, Suite 1200
Washington, D.C. 20005
(202) 737-5600
mshumsky@hpm.com

Fred D. Raschke
Texas Bar No. 16551450
MILLS SHIRLEY L.L.P.
2200 Market Street, Suite 300
Galveston, TX 77550
409.763.2341
fraschke@millsshirley.com

*Counsel for Association for Molecular Pathology
and Dr. Michael Laposata, M.D., Ph.D.*

/s/ Ashley C. Parrish
Ashley C. Parrish (*admitted pro hac vice*)
D.C. Bar No. 464683
Paul Alessio Mezzina (*admitted pro hac vice*)
D.C. Bar No. 999325
Alexander Kazam (*admitted pro hac vice*)
D.C. Bar No. 1708188
KING & SPALDING LLP
1700 Pennsylvania Ave NW, Suite 900
Washington, DC 20006
Tel: (202) 737-0500
aparrish@kslaw.com
pmezzina@kslaw.com
akazam@kslaw.com

Edward F. Fernandes
Texas Bar No. 06932700
Christopher H. Taylor
Texas Bar No. 24013606
KING & SPALDING LLP
500 W. 2nd Street, Suite 1800
Austin, TX 78701
Tel: (512) 457-2000
Fax: (512) 457-2100
efernandes@kslaw.com
ctaylor@kslaw.com

Scott D. Danzis (*admitted pro hac vice*)
D.C. Bar No. 481426
COVINGTON & BURLING
One CityCenter
850 Tenth Street, NW
Washington, DC 20001-4956
Tel: (202) 662-6000
sdanzis@cov.com

*Counsel for American Clinical Laboratory Association,
HealthTrackRx Indiana, Inc., and HealthTrackRx, Inc.*

CERTIFICATE OF SERVICE

I hereby certify that on January 17, 2025, a true and correct copy of this document was served electronically by the Court's CM/ECF system on all counsel of record.

/s/ Ashley C. Parrish
Ashley C. Parrish

Counsel for ACLA Plaintiffs

UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF TEXAS
SHERMAN DIVISION

AMERICAN CLINICAL LABORATORY)	
ASSOCIATION, <i>et al.</i> ,)	
)	
Plaintiffs,)	
)	
v.)	Case No.: 4:24-cv-00479-SDJ
)	
UNITED STATES FOOD AND DRUG)	
ADMINISTRATION, <i>et al.</i> ,)	
)	
Defendants.)	

ASSOCIATION FOR MOLECULAR)	
PATHOLOGY, <i>et al.</i> ,)	
)	
Plaintiffs,)	
)	
v.)	Case No.: 4:24-cv-00824-SDJ
)	
UNITED STATES FOOD AND DRUG)	
ADMINISTRATION, <i>et al.</i> ,)	
)	
Defendants.)	

**ORDER GRANTING REQUEST FOR ORAL ARGUMENT
AND SETTING HEARING**

Having considered Plaintiffs’ Unopposed Request for Oral Argument on the Parties’ Cross-Motions for Summary Judgment, the Court is of the opinion that the request should be **GRANTED**.

The Court will hold an in-person hearing to consider the pending cross-motions for summary judgment. The hearing is set for _____, 2025, at _____.